Findings

What do systematic reviews say?

959 questions · 987 findings · 78 reviews · Haematology

Sort:Best matchNewestHighest certainty Download CSV

No studies found 256 · 25.9%GRADE not reported 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%

Comparison of plasma transfusions vs no plasma transfusions when the INR is 1.5 prior to central venous catheter insertion

Major procedure‐related bleeding · people with abnormal coagulation requiring a central venous catheter

1 finding from 1 review

Plasma transfusions prior to insertion of central lines for people with abnormal coagulation 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 58 participants
Very low

Comparison of plasma transfusions vs no plasma transfusions when the INR is 1.5 prior to central venous catheter insertion

All‐cause mortality · people with abnormal coagulation requiring a central venous catheter

The review found no eligible studies for this question.

1 finding from 1 review

Plasma transfusions prior to insertion of central lines for people with abnormal coagulation 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Comparison of plasma transfusions vs no plasma transfusions when the INR is 1.5 prior to central venous catheter insertion

Respiratory deterioration attributable to transfusion‐associated circulatory overload (TACO), transfusion‐related acute lung injury (TRALI) or transfusion‐associated dyspnoea (TAD) · people with abnormal coagulation requiring a central venous catheter

The review found no eligible studies for this question.

1 finding from 1 review

Plasma transfusions prior to insertion of central lines for people with abnormal coagulation 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Comparison of plasma transfusions vs no plasma transfusions when the INR is 1.5 prior to central venous catheter insertion

Number of participants with minor procedure‐related bleeding within 7 days of surgery · people with abnormal coagulation requiring a central venous catheter

It is very uncertain whether comparison of plasma transfusions changes minor procedure‐related bleeding compared with no plasma transfusions when the INR is 1.5 prior to central venous… (very low certainty).

1 finding from 1 review

Plasma transfusions prior to insertion of central lines for people with abnormal coagulation 2016 · Cochrane Headline outcomes only
RR 0.67 [0.12, 3.7]
1 study · 58 participants
Very low

Comparison of plasma transfusions vs no plasma transfusions when the INR is 1.5 prior to central venous catheter insertion

Proportion of participants receiving plasma transfusions · people with abnormal coagulation requiring a central venous catheter

The review found no eligible studies for this question.

1 finding from 1 review

Plasma transfusions prior to insertion of central lines for people with abnormal coagulation 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Comparison of plasma transfusions vs no plasma transfusions when the INR is 1.5 prior to central venous catheter insertion

Line‐related complications · people with abnormal coagulation requiring a central venous catheter

The review found no eligible studies for this question.

1 finding from 1 review

Plasma transfusions prior to insertion of central lines for people with abnormal coagulation 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Comparison of plasma transfusions vs no plasma transfusions when the INR is 1.5 prior to central venous catheter insertion

Quality of life · people with abnormal coagulation requiring a central venous catheter

The review found no eligible studies for this question.

1 finding from 1 review

Plasma transfusions prior to insertion of central lines for people with abnormal coagulation 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Thrombopoietin mimetics vs placebo

Number of participants with at least 1 bleeding episode · People with chronic bone marrow failure

Thrombopoietin mimetic showed no clear difference in number of participants with at least one bleeding episode compared with placebo (low certainty).

1 finding from 1 review

Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to… 2016 · Cochrane Headline outcomes only
RR 0.86 [0.56, 1.31]
4 studies · 206 participants
Low

Thrombopoietin mimetics vs placebo

Number of participants with severe or life‐threatening bleeding · People with chronic bone marrow failure

Thrombopoietin mimetic showed no clear difference in number of participants with at least one severe or life‐threatening… compared with placebo (low certainty).

1 finding from 1 review

Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to… 2016 · Cochrane Headline outcomes only
RR 0.31 [0.04, 2.26]
1 study · 40 participants
Low

Thrombopoietin mimetics vs placebo

All‐cause mortality · People with chronic bone marrow failure

It is very uncertain whether thrombopoietin mimetic changes all‐cause mortality compared with placebo (very low certainty).

1 finding from 1 review

Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to… 2016 · Cochrane Headline outcomes only
RR 0.74 [0.52, 1.05]
5 studies · 456 participants
Very low

Thrombopoietin mimetics vs placebo

Proportion of patients receiving platelets · People with chronic bone marrow failure

Thrombopoietin mimetic probably leads to lower proportion of participants receiving a platelet transfusion compared with placebo (moderate certainty).

1 finding from 1 review

Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to… 2016 · Cochrane Headline outcomes only
RR 0.76 [0.61, 0.95]
4 studies · 206 participants
Moderate

Thrombopoietin mimetics vs placebo

Blood transfusion reaction · People with chronic bone marrow failure

1 finding from 1 review

Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to… 2016 · Cochrane Headline outcomes only
0.06 [0, 3.44]
1 study · 98 participants
Very low

Thrombopoietin mimetics vs placebo

Thromboembolism · People with chronic bone marrow failure

It is very uncertain whether thrombopoietin mimetic changes thromboembolism compared with placebo (very low certainty).

1 finding from 1 review

Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to… 2016 · Cochrane Headline outcomes only
RR 1.41 [0.39, 5.01]
5 studies · 456 participants
Very low

Thrombopoietin mimetics vs placebo

Adverse drug reactions · People with chronic bone marrow failure

Thrombopoietin mimetic showed no clear difference in drug reactions compared with placebo (low certainty).

1 finding from 1 review

Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to… 2016 · Cochrane Headline outcomes only
RR 1.12 [0.83, 1.51]
5 studies · 455 participants
Low

Thrombopoietin mimetics vs placebo

Number of red cell transfusions per participant · People with chronic bone marrow failure

1 finding from 1 review

Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to… 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 98 participants
GRADE not reported

Intervention not reported

All cause mortality · cancer patients receiving myelotoxic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Incidence of febrile neutropenia · cancer patients receiving myelotoxic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Incidence of severe infections (Grade III or IV) · cancer patients receiving myelotoxic chemotherapy

The intervention showed no clear difference in incidence of severe infections (Grade III or IV) (low certainty).

1 finding from 1 review

Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients… 2015 · Cochrane Headline outcomes only
RR 1.55 [0.86, 2.8]
1 study · 115 participants
Low

Intervention not reported

Adverse events Toxic deaths · cancer patients receiving myelotoxic chemotherapy

The intervention showed no clear difference in adverse events Toxic deaths (low certainty).

1 finding from 1 review

Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients… 2015 · Cochrane Headline outcomes only
RR 1.32 [0.3, 5.69]
1 study · 115 participants
Low

Intervention not reported

Infection‐related mortality · cancer patients receiving myelotoxic chemotherapy

1 finding from 1 review

Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients… 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Very low